Furthermore, incorporating IGFBP-1 into clinical decision-making may facilitate more equitable treatment strategies, ultimately narrowing the gap in cardiovascular outcomes between women and men with PAD [52]. Here, IGFBP1 is linked to peripheral arterial disease.